These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 28060735)

  • 41. The dual EGFR/HER2 inhibitor lapatinib synergistically enhances the antitumor activity of the histone deacetylase inhibitor panobinostat in colorectal cancer models.
    LaBonte MJ; Wilson PM; Fazzone W; Russell J; Louie SG; El-Khoueiry A; Lenz HJ; Ladner RD
    Cancer Res; 2011 May; 71(10):3635-48. PubMed ID: 21464044
    [TBL] [Abstract][Full Text] [Related]  

  • 42. HBx sensitizes hepatocellular carcinoma cells to lapatinib by up-regulating ErbB3.
    Chen JY; Chen YJ; Yen CJ; Chen WS; Huang WC
    Oncotarget; 2016 Jan; 7(1):473-89. PubMed ID: 26595522
    [TBL] [Abstract][Full Text] [Related]  

  • 43. EGF receptor inhibitors increase ErbB3 mRNA and protein levels in breast cancer cells.
    Grøvdal LM; Kim J; Holst MR; Knudsen SL; Grandal MV; van Deurs B
    Cell Signal; 2012 Jan; 24(1):296-301. PubMed ID: 21951604
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Therapeutic targeting of multiple signaling pathways in malignant pleural mesothelioma.
    Mukohara T; Civiello G; Johnson BE; Janne PA
    Oncology; 2005; 68(4-6):500-10. PubMed ID: 16020981
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Antitumor and antiangiogenic effect of the dual EGFR and HER-2 tyrosine kinase inhibitor lapatinib in a lung cancer model.
    Diaz R; Nguewa PA; Parrondo R; Perez-Stable C; Manrique I; Redrado M; Catena R; Collantes M; Peñuelas I; Díaz-González JA; Calvo A
    BMC Cancer; 2010 May; 10():188. PubMed ID: 20459769
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Lapatinib-resistant cancer cells possessing epithelial cancer stem cell properties develop sensitivity during sphere formation by activation of the ErbB/AKT/cyclin D2 pathway.
    Ohnishi Y; Yasui H; Kakudo K; Nozaki M
    Oncol Rep; 2016 Nov; 36(5):3058-3064. PubMed ID: 27633099
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Anti-metastasis effect of fucoidan from Undaria pinnatifida sporophylls in mouse hepatocarcinoma Hca-F cells.
    Wang P; Liu Z; Liu X; Teng H; Zhang C; Hou L; Zou X
    PLoS One; 2014; 9(8):e106071. PubMed ID: 25162296
    [TBL] [Abstract][Full Text] [Related]  

  • 48. ErbB3 inhibitory surrobodies inhibit tumor cell proliferation in vitro and in vivo.
    Foreman PK; Gore M; Kobel PA; Xu L; Yee H; Hannum C; Ho H; Wang SM; Tran HV; Horowitz M; Horowitz L; Bhatt RR
    Mol Cancer Ther; 2012 Jul; 11(7):1411-20. PubMed ID: 22553357
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Lapatinib-induced NF-kappaB activation sensitizes triple-negative breast cancer cells to proteasome inhibitors.
    Chen YJ; Yeh MH; Yu MC; Wei YL; Chen WS; Chen JY; Shih CY; Tu CY; Chen CH; Hsia TC; Chien PH; Liu SH; Yu YL; Huang WC
    Breast Cancer Res; 2013 Nov; 15(6):R108. PubMed ID: 24216290
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Preclinical Evaluation of Safety of Fucoidan Extracts From Undaria pinnatifida and Fucus vesiculosus for Use in Cancer Treatment.
    Mathew L; Burney M; Gaikwad A; Nyshadham P; Nugent EK; Gonzalez A; Smith JA
    Integr Cancer Ther; 2017 Dec; 16(4):572-584. PubMed ID: 29096568
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Bruton's Tyrosine Kinase Inhibitors Prevent Therapeutic Escape in Breast Cancer Cells.
    Wang X; Wong J; Sevinsky CJ; Kokabee L; Khan F; Sun Y; Conklin DS
    Mol Cancer Ther; 2016 Sep; 15(9):2198-208. PubMed ID: 27256378
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Activation of EGFR, HER2 and HER3 by neurotensin/neurotensin receptor 1 renders breast tumors aggressive yet highly responsive to lapatinib and metformin in mice.
    Dupouy S; Doan VK; Wu Z; Mourra N; Liu J; De Wever O; Llorca FP; Cayre A; Kouchkar A; Gompel A; Forgez P
    Oncotarget; 2014 Sep; 5(18):8235-51. PubMed ID: 25249538
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The ErbB3-binding protein EBP1 modulates lapatinib sensitivity in prostate cancer cells.
    Awasthi S; Ezelle H; Hassel BA; Hamburger AW
    Mol Cell Biochem; 2015 Jul; 405(1-2):177-86. PubMed ID: 25876877
    [TBL] [Abstract][Full Text] [Related]  

  • 54. ErbB3 expression promotes tumorigenesis in pancreatic adenocarcinoma.
    Liles JS; Arnoletti JP; Tzeng CW; Howard JH; Kossenkov AV; Kulesza P; Heslin MJ; Frolov A
    Cancer Biol Ther; 2010 Sep; 10(6):555-63. PubMed ID: 20647770
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Dual blockade of HER2 in HER2-overexpressing tumor cells does not completely eliminate HER3 function.
    Garrett JT; Sutton CR; Kuba MG; Cook RS; Arteaga CL
    Clin Cancer Res; 2013 Feb; 19(3):610-9. PubMed ID: 23224399
    [TBL] [Abstract][Full Text] [Related]  

  • 56. MiR-16 mediates trastuzumab and lapatinib response in ErbB-2-positive breast and gastric cancer via its novel targets CCNJ and FUBP1.
    Venturutti L; Cordo Russo RI; Rivas MA; Mercogliano MF; Izzo F; Oakley RH; Pereyra MG; De Martino M; Proietti CJ; Yankilevich P; Roa JC; Guzmán P; Cortese E; Allemand DH; Huang TH; Charreau EH; Cidlowski JA; Schillaci R; Elizalde PV
    Oncogene; 2016 Dec; 35(48):6189-6202. PubMed ID: 27157613
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Inhibition of the HER2-YB1-AR axis with Lapatinib synergistically enhances Enzalutamide anti-tumor efficacy in castration resistant prostate cancer.
    Shiota M; Bishop JL; Takeuchi A; Nip KM; Cordonnier T; Beraldi E; Kuruma H; Gleave ME; Zoubeidi A
    Oncotarget; 2015 Apr; 6(11):9086-98. PubMed ID: 25871401
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The anti-erbB3 antibody MM-121/SAR256212 in combination with trastuzumab exerts potent antitumor activity against trastuzumab-resistant breast cancer cells.
    Huang J; Wang S; Lyu H; Cai B; Yang X; Wang J; Liu B
    Mol Cancer; 2013 Nov; 12(1):134. PubMed ID: 24215614
    [TBL] [Abstract][Full Text] [Related]  

  • 59. HER2 signaling regulates HER2 localization and membrane retention.
    Jeong J; Kim W; Kim LK; VanHouten J; Wysolmerski JJ
    PLoS One; 2017; 12(4):e0174849. PubMed ID: 28369073
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Erlotinib is a viable treatment for tumors with acquired resistance to cetuximab.
    Brand TM; Dunn EF; Iida M; Myers RA; Kostopoulos KT; Li C; Peet CR; Wheeler DL
    Cancer Biol Ther; 2011 Sep; 12(5):436-46. PubMed ID: 21725209
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.